$1.09 Billion is the total value of Consonance Capital Management LP's 26 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 47.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RDUS | Buy | RADIUS HEALTH INC | $104,258,000 | +23.9% | 2,900,893 | +9.5% | 9.53% | +25.3% |
| SPPI | Sell | SPECTRUM PHARMACEUTICALS INC | $99,812,000 | -28.7% | 6,203,356 | -16.0% | 9.12% | -27.8% |
| CORT | Sell | CORCEPT THERAPEUTICS INC | $85,349,000 | -18.2% | 5,188,417 | -10.2% | 7.80% | -17.3% |
| RTRX | Buy | RETROPHIN INC | $82,584,000 | +7.5% | 3,693,371 | +1.3% | 7.55% | +8.8% |
| PCRX | Buy | PACIRA PHARMACEUTICALS INC | $82,078,000 | +12.2% | 2,634,916 | +64.4% | 7.50% | +13.5% |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $63,700,000 | – | 566,926 | +100.0% | 5.82% | – |
| NUVA | Buy | NUVASIVE INC | $57,406,000 | +45.4% | 1,099,523 | +62.9% | 5.25% | +47.1% |
| URGN | Buy | UROGEN PHARMA LTD | $56,955,000 | +67.0% | 1,146,197 | +25.1% | 5.20% | +69.0% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $54,183,000 | +2814.6% | 3,206,073 | +1279.6% | 4.95% | +2847.0% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $53,367,000 | -45.6% | 17,729,933 | -27.6% | 4.88% | -45.0% |
| VNDA | New | VANDA PHARMACEUTICALS INC | $51,768,000 | – | 3,072,275 | +100.0% | 4.73% | – |
| STML | Buy | STEMLINE THERAPEUTICS INC | $39,881,000 | +8.8% | 2,606,598 | +10.9% | 3.64% | +10.1% |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $32,927,000 | – | 1,658,795 | +100.0% | 3.01% | – |
| VCEL | Sell | VERICEL CORP | $30,891,000 | +67.6% | 3,104,592 | -8.2% | 2.82% | +69.7% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $30,725,000 | -65.5% | 272,700 | -59.6% | 2.81% | -65.1% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $29,123,000 | +86.1% | 2,339,184 | +108.9% | 2.66% | +88.3% |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $25,781,000 | +38.2% | 12,576,002 | +78.0% | 2.36% | +39.8% |
| SVRA | Sell | SAVARA INC | $24,943,000 | -39.0% | 2,711,190 | -1.6% | 2.28% | -38.3% |
| QURE | New | UNIQURE NV | $24,559,000 | – | 1,045,065 | +100.0% | 2.24% | – |
| ADMA | Sell | ADMA BIOLOGICS INC | $15,314,000 | +41.7% | 3,329,234 | -1.1% | 1.40% | +43.3% |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $11,937,000 | -31.8% | 4,994,719 | +11.6% | 1.09% | -30.9% |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $9,783,000 | – | 446,100 | +100.0% | 0.89% | – |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $8,322,000 | -9.7% | 142,943 | -0.0% | 0.76% | -8.7% |
| RARX | New | RA PHARMACEUTICALS INC | $7,725,000 | – | 1,454,761 | +100.0% | 0.71% | – |
| CVRS | Sell | CORINDUS VASCULAR ROBOTICS I | $6,268,000 | +3.7% | 4,574,835 | -23.6% | 0.57% | +4.9% |
| FLXN | New | FLEXION THERAPEUTICS INC | $4,648,000 | – | 207,392 | +100.0% | 0.42% | – |
| SPNE | Exit | SEASPINE HLDGS CORP | $0 | – | -21,428 | -100.0% | -0.02% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -783,869 | -100.0% | -4.47% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -2,079,311 | -100.0% | -6.04% | – |
| MDXG | Exit | MIMEDX GROUP INC | $0 | – | -5,990,682 | -100.0% | -6.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.